Scholte HR, Luyt-Houwen IEM, Vaandrager-Verduin MHM
The new surcharge for filing a continuing application six or more years after the earliest priority date ($2,700) and the nine-year surcharge ($4,000) directly penalize the practice of keeping a patent family alive through long chains of continuation filings a standard lifecycle management tactic for blockbuster drugs
Esta comparacin es til para priorizar la seguridad, la transparencia y la variedad de promociones
Keywords: autoimmune diseases, DPP4 inhibitors, inflammatory disorders, MERS-CoV, diabetes mellitus, COVID-19 Introduction Dipeptidyl-peptidase 4 (DPP4), also known as CD26, is a significant enzyme belonging to the SC serine peptidase clan, specifically within its subfamily 9b